The impact of Mexidol on improving quality of life parameters and functional kidney status as part of complex therapy for cognitive impairments in comorbid patients with microalbuminuria against the background of arterial hypertension and type 2 diabetes mellitus

Tolkacheva V.V.; Karapetyan L.V.; Ezhova L.G.; Khutsishvili N.I.; Kontareva N.I.; Galochkin S.A.; Kazakhmedov E.R.; Kobalava Z.D.

doi:https://doi.org/10.17116/kardio202518041478

Tolkacheva V.V.

Peoples’ Friendship University of Russia named after Patris Lumumber

ORCID: 0000-0001-6847-8797

Karapetyan L.V.

Peoples’ Friendship University of Russia named after Patris Lumumber

ORCID: 0000-0002-6697-2393

Ezhova L.G.

Peoples’ Friendship University of Russia named after Patrice Lumumba

ORCID: 0000-0003-0727-631X

Khutsishvili N.I.

Peoples’ Friendship University of Russia named after Patris Lumumber

ORCID: 0009-0009-2669-8092

Kontareva N.I.

Peoples’ Friendship University of Russia named after Patrice Lumumba

Galochkin S.A.

Peoples’ Friendship University of Russia named after Patris Lumumber

ORCID: 0000-0001-7370-8606

Kazakhmedov E.R.

Peoples’ Friendship University of Russia named after Patris Lumumber

ORCID: 0000-0002-6274-8933

Kobalava Z.D.

Peoples’ Friendship University of Russia named after Patris Lumumber

ORCID: 0000-0002-5873-1768

The impact of Mexidol on improving quality of life parameters and functional kidney status as part of complex therapy for cognitive impairments in comorbid patients with microalbuminuria against the background of arterial hypertension and type 2 diabetes mellitus

Authors:

Tolkacheva V.V., Karapetyan L.V., Ezhova L.G., Khutsishvili N.I., Kontareva N.I., Galochkin S.A., Kazakhmedov E.R., Kobalava Z.D.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2025;18(4): 478‑478

DOI: 10.17116/kardio202518041478

Read: 742 times

Contact the author

Table of contents

To cite this article:

Tolkacheva VV, Karapetyan LV, Ezhova LG, et al. . The impact of Mexidol on improving quality of life parameters and functional kidney status as part of complex therapy for cognitive impairments in comorbid patients with microalbuminuria against the background of arterial hypertension and type 2 diabetes mellitus. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;18(4):478‑478. (In Russ.)
https://doi.org/10.17116/kardio202518041478

Подписка 2026 Кардиология и сердечно-сосудистая хирургия (Russian Journal of Cardiology and Cardiovascular Surgery)

Использование инфографики авторами научных работ

OBJECTIVE

Evaluation of the effect of Mexidol as part of the complex therapy of cognitive impairment for 10 weeks on cognitive status, quality of life parameters and kidney function in comorbid patients with microalbuminuria on the background of arterial hypertension (AH) and type 2 diabetes mellitus (DM).

METHODS

The prospective, open randomized trial included 60 comorbid patients (1:1) with hypertension and type 2 diabetes with cognitive impairment< 24 points on the Montreal Cognitive Function Assessment Scale (MoCA) and microalbuminuria (urinary albumin/creatinine >30 mg/g). The average age of the patients was 64.8±10.3 years, 50% were male. 30 patients were included in the standard therapy group with additional administration of Mexidol (200 mg intramuscularly once a day for 14 days, then 125 mg 3 times a day for 8 weeks) and 30 patients in the standard therapy group. Initially and at the end of the study, the effect of therapy on the cognitive status of patients was assessed using the Montreal Cognitive Function Assessment Scale (MOCA), quality of life parameters based on the results of the Minnesota (MLHFQ), Kansas (Kansas City Cardiomyopathy Questionnaire, KCCQ) and the SF-36 questionnaire «Quality of Life Assessment», the severity and dynamics of asthenic syndrome according to the subjective asthenia assessment scale (MFI-20) and the level of anxiety on the Beck scale. Initially, after 14 days and at the end of the study, the functional state of the kidneys was assessed by serum creatinine and cystatin C, the estimated glomerular filtration rate of GFR by creatinine level (eGFRcr), eGFR by cystatin C level (eGFRCCcys) in the blood and the ratio of albumin/creatinine in urine.

RESULTS

Patients who received Mexidol in addition to standard therapy showed a significant improvement in cognitive function on the MoCA scale by 14% (p<0.001), an improvement in the quality of life according to the Minnesota questionnaire by 38% (p<0.001), according to the Kansas questionnaire by 12% (p=0.05), a decrease in the severity of asthenic syndrome by 20% (p<0.001) and anxiety levels by 33% (p<0.001), a significant improvement in the functional state of the kidneys in the form of a decrease in albuminuria by 71% (p<0.001), creatinine by 7.3% (p<0.01), cystatin C by 18% (p<0.001), increased eGFRcr by 8.7% (p<0.001), eGFRcys by 11.28% (p<0.001).

CONCLUSION

Mexidol, when added to standard therapy in comorbid patients with microalbuminuria on the background of hypertension and type 2 diabetes, significantly improves cognitive status, quality of life parameters, reduces the severity of asthenic syndrome and anxiety levels, and improves the functional state of the kidneys.

Keywords:

microalbuminuria

cognitive impairment

cognitive status

quality of life

diabetic nephropathy

functional state of kidneys

Mexidol

Authors:

Tolkacheva V.V.

Peoples’ Friendship University of Russia named after Patris Lumumber

ORCID: 0000-0001-6847-8797

Karapetyan L.V.

Peoples’ Friendship University of Russia named after Patris Lumumber

ORCID: 0000-0002-6697-2393

Ezhova L.G.

Peoples’ Friendship University of Russia named after Patrice Lumumba

ORCID: 0000-0003-0727-631X

Khutsishvili N.I.

Peoples’ Friendship University of Russia named after Patris Lumumber

ORCID: 0009-0009-2669-8092

Kontareva N.I.

Peoples’ Friendship University of Russia named after Patrice Lumumba

Galochkin S.A.

Peoples’ Friendship University of Russia named after Patris Lumumber

ORCID: 0000-0001-7370-8606

Kazakhmedov E.R.

Peoples’ Friendship University of Russia named after Patris Lumumber

ORCID: 0000-0002-6274-8933

Kobalava Z.D.

Peoples’ Friendship University of Russia named after Patris Lumumber

ORCID: 0000-0002-5873-1768

Close metadata

References:

Kryukov NN, Portnova EV. Role of hypertension and supraventricular arrhythmias in cognitive impairments: the current problem state. Ration Pharmacother Cardiol. 2013;9(5):519-524. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-5-519-524
Kobalava ZhD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI, Barbarash OL, Bobkova NV, Boytsov SA, Bubnova MG, Vavilova TV, Villevalde SV, Galyavich AS, Glezer MG, Grineva EN, Grinstein YuI, Drapkina OM, Zhernakova YuV, Zvartau NE, Irtyuga OB, Kislyak OA, Koziolova NA, Kosmacheva ED, Kotovskaya YuV, Libis RA, Lopatin YuM, Nebiridze DV, Nedoshivin AO, Nikulina SYu, Ostroumova OD, Oschepkova EV, Ratova LG, Salasiuk AS, Skibitsky VV, Tkacheva ON, Troitskaya E A, Chazova IE, Chesnikova AI, Chumakova GA, Shalnova SA, Shestakova MV, Yakushin SS, Yanishevsky SN. 2024 Clinical practice guidelines for Hypertension in adults. Russian Journal of Cardiology. 2024;29(9):6117. (In Russ.). https://doi.org/10.15829/1560-4071-2024-6117.EDNGUEWLU
Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874-2071. https://doi.org/10.1097/HJH.0000000000003480
Howangyin KY, Silvestre J-S. Diabetes mellitus and ischemic diseases: molecular mechanisms of vascular repair dysfunction. Arteriosclerosis Thrombosis Vasc Biol. 2014;34(6):1126-1135. https://doi.org/10.1161/atvbaha.114.303090
Tanashyan MM, Lagoda OV, Antonova KV, Raskurazhev AA. The main pathogenetic mechanisms of vascular cerebral pathology associated with atherosclerosis and metabolic syndrome: the search for correction approaches. Clinical neurology. 2016;10(2):5-9. (In Russ.).
Tanashyan MM, Lagoda OV, Antonova KV. Cerebrovascular diseases: perspectives of pathogenetic metabolic haemangiocorrective treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2015;115(9):170-175. (In Russ.).
Tanashyan MM, Lagoda OV, Antonova KV. Chronic cerebrovascular diseases on the background of metabolic syndrome: new approaches to treatment. J Neur Psychiatry n.a. S.S. Korsakov. 2012;112(11):21-26. (In Russ.).
Chu X, Kirgizova OY. Metabolic syndrome: some results and prospects for solving the problem. Acta Biomedica Scientifica. 2016;1(5):187-194. (In Russ.). https://doi.org/10.12737/23422(InRuss.).
Yudin AA, Belyaev AN. Pathogenetic correction of renal failure in acute obstructive cholestasis. Modern problems of science and education. 2010;4:36-42. (In Russ.).
Drachuk VM, Zamorskiy II, Goroshko AM. Comparative assessment of the nephroprotective effect of taurine and mexidol in ischemic-reperfusion acute kidney injury. Bukovinsky Medical Bulletin. 2018;22(2):33-43. (In Russ.).
Borovkova NYu, Borovkov NN, Bakka TE. Acute kidney injury in patients with acute ST-segment elevation myocardial infarction. Modern technologies in medicine. 2017;9(3):56-61. (In Russ.).
Voronina TA, Litvinova SA, Gladysheva NA, Shulyndin AV. The known and new ideas about the mechanism of action and the spectrum of effects of Mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(5):22-33. (In Russ.). https://doi.org/10.17116/jnevro202512505122
Instructions for medical use of the medicinal product Mexidol®. State Register of Medicines. (In Russ.). https://www.vidal.ru/drugs/mexidol__32969
Fedin AI, Zakharov VV, Tanashyan MM, Chukanova EI, Majidova EN, Shchepankevich LA, Ostroumova OD. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). S.S. Korsakov Journal of Neurology and Psychiatry=Zhurnal nevrologii i psikhiatrii imeni SS. Korsakova. 2021;121(11):7-16. (In Russ.). https://doi.org/10.17116/jnevro20211211117
Zaharov VV, Ostroumova OD, Kochetkov AI, Klepikova MV, Fedin AI. International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO): subanalysis in patients with arterial hypertension. Russian Journal of Preventive Medicine. 2024;27(10):72-83. (In Russ., In Engl.). https://doi.org/10.17116/profmed20242710172
Kuzmin OB, Buchneva NV, Zhezha VV. Pharmacological correction of toxic kidney damage by antioxidants during the administration of nephrotoxic drugs. Nephrology. 2015;19(3):78-85. (In Russ.).
Shilov EM, Fomin VV, Shvetsov MY. Chronic kidney disease and nephroprotective therapy: A methodological guide for doctors. Moscow: MEDpress-inform, 2012. 83 p. (In Russ.).
Smirnov AV, Dobronravov VA, Kayukov IG. Acute kidney injury is a new concept in neurology. Clinical Nephrology. 2009(1):11-15. (In Russ.).
Bolotova EV, Lushpay NYu, Kovrigina IV. Improvement of the efficacy of treatment of hypertensive encephalohathy by using Mexidol. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova=S.S. Korsakov Journal of Neurology and Psychiatry. 2018; 118(4):61-64 (In Russ.). https://dx.doi.org/10.17116/jnevro20181184161-64.EDN:USBEEW.
Pugacheva EL. Efficacy of Mexidol in patients with type 2 diabetes mellitus with neurological complications. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(5):84-89. (In Russ.). https://doi.org/10.17116/jnevro202212205184
Korolkova EE. Nephroprotective effect of mexidol in shock injuries. Experimental and clinical pharmacology. 2000;63(2):32-35. (In Russ.).
H. Gao, Q. Hu, H. Xie, et al. Angiotensin II promotes podocyte injury by activating Arf6-Erk1/2-Nox4 signaling pathway. PLoS One. 2020:15:e0229747